Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia

Leukemia

Volumn 22, Issue 12, 2008, Pages 2184-2192

  Weinberg, J B ^a   Volkheimer, A D ^a   Mihovilovic, M ^b   Jiang, N ^a   Chen, Y ^a   Bond, K ^a   Moore, J O ^b   Gockerman, J P ^b   Diehl, L F ^b   de Castro, C M ^b   Rizzieri, D A ^b   Levesque, M C ^b   DeKroon, R ^b   Strittmatter, W J ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; APOPTOSIS; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; RISK ASSESSMENT; SURVIVAL TIME;

EID: 57849164478     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.241     Document Type: Article

References (30)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Keating MJ. Chronic lymphocytic leukemia. In: Henderson ES, Lister TA, Greaves MF (eds). Leukemia, 7th edn. Saunders: Philadelphia, 2002, pp 131-151.
3. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391-1400.
4. DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M et al. APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2. Circ Res 2006; 99: 829-836.
5. DeKroon RM, Mihovilovic M, Goodger ZV, Robinette JB, Sullivan PM, Saunders AM et al. ApoE genotype-specific inhibition of apoptosis. J Lipid Res 2003; 44: 1566-1573.
6. Weinberg JB, Volkheimer AD, Chen Y, Beasley BE, Jiang N, Lanasa MC et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007; 82 1063-1070.
7. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
8. Volkheimer AD, Weinberg JB, Beasley BE, Whitesides JF, Gockerman JP, Moore JO et al. Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: Evidence for antigen-driven intraclonal diversification. Blood 2007; 109: 1559-1567.
9. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
10. Mihovilovic M, Hulette C, Gilbert JR. Strategy to analyze thymic transcription of alpha-3 neuronal nicotinic acetylcholine receptor submit. Methods Neurosc 1993; 12: 169-190.
11. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: Insight from animal and human studies. Clin Chim Acta 1999; 286: 115-143.
12. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb 1994; 14: 1105-1113.
13. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106: 650-657.
14. Nuckel H, Huttmann A, Klein-Hitpass L, Schroers R, Fuhrer A, Sellmann L et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47 1053-1061.
15. Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216-1223.
16. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
17. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
18. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
19. Schwarz JK, Yarbro JW. Scientific basis of cancer chemotherapy. In: Perry MC (ed). The Chemotherapy Source Book. Lippincott Williams & Wilkins: Philadelphia, 2001, pp 1-6.
20. Ji ZS, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. J Biol Chem 1998; 273: 13452-13460.
21. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 1993; 268: 9369-9375.
22. Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 2006; 47: 1477-1480.
23. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
24. Narasimhan P, Amaral L. Lymphopenic response of patients presenting with chronic lymphocytic leukemia associated with carcinoma of the prostate to diethylstilbestrol: Correlation of response to the in vitro synthesis of RNA by patient lymphocytes and its relationship to transcortin. Am J Hematol 1980; 8: 369-375.
25. Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005; 24: 3797-3809.
26. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87: 677-682.
27. Wang JM, Irwin RW, Brinton RD. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc Natl Acad Sci USA 2006; 103: 16983-16988.
28. Raber J, Bongers G, LeFevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci 2002; 22: 5204-5209.
29. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: A meta-analysis. J Lipid Res 1992; 33: 447-454.
30. Ferrieres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects. Arterioscler Thromb 1994; 14: 1553-1560.